. Long-term infliximab therapy is needed for sustained steroid-free remission in patients with ulcerative colitis.
Long-term infliximab therapy is needed for sustained steroid-free remission in patients with ulcerative colitis
to 24 months of follow-up, retrospective studies report heterogeneous remission rates for UC between 17% and 90%. [2] [3] [4] This wide range of remission may be due to the duration of IFX exposure, therefore affecting outcomes after IFX discontinuation. In small cohorts of 4 to 51 patients in remission, the rate of relapse following IFX discontinuation ranged from 0% to 59% after 6.5 months to 4.5 years of follow-up. 2, 5 This rate of relapse leads to difficult decision-making regarding maintenance therapy with IFX.
We reviewed the medical charts of 100 patients treated with IFX for UC in a single gastroenterology unit between 2005 and 2012. Clinical remission was defined as a partial Mayo score of 2 points or lower, without bleeding; response, by a decrease of 2 points; and relapse, by an increase of 2 points. Survival curves were estimated by the Kaplan-Meier method and compared using the log rank statistic. A Cox proportional hazards regression model was used to assess independent predictors of each event.
Seventeen of the 100 patients were treated for acute, severe UC (refractory to intravenous steroids); 83, for steroid dependency or secondary to immunosuppressive therapy failure. In total, 52% of patients had concomitant immunosuppressive therapy at baseline. In conclusion, after a 5-year follow-up IFX discontinuation in UC patients led to a high rate of relapse and was inversely associated with sustained remission. In our series, one-third of patients underwent colectomy, one-third relapsed and only one-third experienced a sustained clinical remission. These results support the use of long-term IFX maintenance therapy in these patients.
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